SEC Form 4

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			of Section So(n) of the investment Company Act of 1940				
1. Name and Adda Burke Willia	1 0	Person*	2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]		tionship of Reporting Pe all applicable) Director	10% Owner	
(Last) 125 SUMMER	Last) (First) (Middle) 25 SUMMER STREET		3. Date of Earliest Transaction (Month/Day/Year) 06/12/2020		Officer (give title below) EVP, Chief Finan	Other (specify below) cial Officer	
(Street) BOSTON (City)	MA (State)	02110 (Zip)	 4. If Amendment, Date of Original Filed (Month/Day/Year) 	6. Indiv Line) X	idual or Joint/Group Fili Form filed by One Re Form filed by More th Person	porting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr.4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)8)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	06/12/2020		A ⁽¹⁾		22,334 ⁽¹⁾	A	\$0	35,029 ⁽²⁾	D	
Common Stock	06/12/2020		S ⁽³⁾		197 ⁽³⁾	D	\$89.29	34,832 ⁽²⁾	D	
Common Stock	06/15/2020		S ⁽⁴⁾		9,720 ⁽⁴⁾	D	\$87.71	25,112 ⁽²⁾	D	
Common Stock	06/16/2020		S ⁽⁵⁾		5,259	D	\$90.36 ⁽⁶⁾	19,853 ⁽²⁾	D	
Common Stock	06/16/2020		S ⁽⁵⁾		6,146	D	\$91.38(7)	13,707 ⁽²⁾	D	
Common Stock	06/16/2020		S ⁽⁵⁾		1,209	D	\$92.09 ⁽⁸⁾	12,498 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispe of (D	r osed) 1. 3, 4	6. Date Exerc Expiration Da (Month/Day/\	ate	7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020

2. This number includes unvested restricted stock units ("RSUs") previously reported.

3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover transaction and does not represent a discretionary trade by the reporting person.

5. Transaction pursuant to an existing 10b5-1 trading plan.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$89.94 to \$90.94, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) through (8) to this Form 4.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$90.95 to \$91.95, inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.97 to \$92.24, inclusive.

/s/ Thomas V. Powers, attorney-in-fact for Mr. Burke

** Signature of Reporting Person Date

06/16/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.